We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

59 hedge funds and large institutions have $47.6M invested in Orchestra BioMed in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

5% more funds holding

Funds holding: 56 → 59 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.63% less ownership

Funds ownership: 49.97% → 47.33% (-2.6%)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

41% less capital invested

Capital invested by funds: $81.3M → $47.6M (-$33.7M)

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
22
Increased
14
Reduced
16
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$1.33M
2
Millennium Management
Millennium Management
New York
+$1.2M
3
Renaissance Technologies
Renaissance Technologies
New York
+$494K
4
DMKJ
David M. Knott Jr
+$292K
5
RI
RTW Investments
New York
+$292K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.69M
2
State Street
State Street
Massachusetts
-$1M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$856K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$439K
5
Northern Trust
Northern Trust
Illinois
-$404K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$75.6K +$82.4K +28,221 New
HF
27
HRT Financial
New York
$75K +$82.4K +28,217 New
TRCT
28
Tower Research Capital (TRC)
New York
$74.8K +$74.9K +25,666 +1,138%
UBS Group
29
UBS Group
Switzerland
$70.1K +$25.9K +8,869 +51%
BCM
30
Bridgeway Capital Management
Texas
$67K +$73K +25,000 New
JG
31
Jain Global
New York
$65.6K +$71.4K +24,462 New
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$59.7K +$64.8K +22,207 New
Bank of America
33
Bank of America
North Carolina
$57.8K +$16.6K +5,678 +36%
PAS
34
Point72 Asia (Singapore)
Singapore
$50.1K +$54.6K +18,710 New
Jane Street
35
Jane Street
New York
$49.6K +$54K +18,513 New
CSS
36
Cubist Systematic Strategies
Connecticut
$47.5K +$51.7K +17,716 New
XT
37
XTX Topco
Cayman Islands
$45.1K +$49.1K +16,817 New
Creative Planning
38
Creative Planning
Kansas
$40.2K +$43.8K +15,000 New
AFG
39
ABLE Financial Group
Arizona
$35.9K – – –
Morgan Stanley
40
Morgan Stanley
New York
$35.9K -$54.7K -18,752 -58%
CFM
41
Catalyst Funds Management
Australia
$30.6K +$33.3K +11,400 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$21K +$21.1K +7,215 +1,175%
Citigroup
43
Citigroup
New York
$20.5K -$27.9K -9,557 -56%
Wells Fargo
44
Wells Fargo
California
$12K -$26.2K -8,979 -67%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$6.45K +$1.66K +570 +31%
HI
46
Harbour Investments
Wisconsin
$5.33K – – –
LFG
47
Larson Financial Group
Missouri
$5.31K +$444 +152 +8%
Fidelity Investments
48
Fidelity Investments
Massachusetts
$4.41K +$1.6K +550 +50%
Barclays
49
Barclays
United Kingdom
$2.34K -$72.2K -24,735 -97%
SS
50
SBI Securities
Japan
$1.82K +$1.99K +680 +68,000%
1
2
3 4

OBIO Hedge Fund Activity: Q2 2025 in Review

59 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2025, worth a combined $47.6M — down 41% from $81.3M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OBIO positions and 19 closed out — a net gain of 3 holders — while 14 added to existing stakes and 16 trimmed.

The largest buyer was Knoll Capital Management, opening a new position worth an estimated $1.33M. The largest seller was BlackRock, cutting an estimated $3.69M.

  • 59 institutional investors held Orchestra BioMed (OBIO) as of Q2 2025, up from 56 in Q1 2025.
  • Funds reported $47.6M of Orchestra BioMed stock for Q2 2025, down 41% quarter-over-quarter.
  • 22 funds opened new Orchestra BioMed positions in Q2 2025 and 19 closed out, a net change of +3 holders.
  • The largest Orchestra BioMed buyer in Q2 2025 was Knoll Capital Management, an estimated $1.33M added.
  • The largest Orchestra BioMed seller in Q2 2025 was BlackRock, an estimated $3.69M sold.

Based on aggregated 13F filings for Q2 2025.